Page 92 - Read Online

Pippione et al. Steroidogenic enzymes in prostate cancer

androgen receptor: a new approach for the treatment of advanced androgen receptor downregulators as an approach to treatment of
prostate cancer. Oncologist 2016;21:1427-35. advanced prostate cancer. Bioorg Med Chem Lett 2011;21:5442-5.
141. Andersen RJ. Sponging off nature for new drug leads. Biochem 155. Gustafson JL, Neklesa TK, Cox CS, Roth AG, Buckley DL, Tae
Pharmacol 2017;139:3-14. HS, Sundberg TB, Stagg DB, Hines J, McDonnell DP, Norris JD,
142. Shaffer PL, Jivan A, Dollins DE, Claessens F, Gewirth DT. Structural Crews CM. Small-molecule-mediated degradation of the androgen
basis of androgen receptor binding to selective androgen response receptor through hydrophobic tagging. Angew Chem Int Ed Engl
elements. Proc Natl Acad Sci U S A 2004;101:4758-63. 2015;54:9659-62.
143. Diamond M, Jones J, Renslo A. Androgen receptor inhibitors, 156. Lai AC, Crews CM. Induced protein degradation: an emerging drug
including tetrahydropyrvinium derivatives and benzoxazole discovery paradigm. Nat Rev Drug Discov 2017;16:101-14.
compounds, and their therapeutic use. Oakland, USA: University of 157. Chu FM, Sartor O, Gomella L, Rudo T, Somerville MC, Hereghty
California; 2009. p. 67. B, Manyak MJ. A randomised, double-blind study comparing the
144. Lim M, Otto-Duessel M, He M, Su L, Nguyen D, Chin E, Alliston T, addition of bicalutamide with or without dutasteride to GnRH
Jones JO. Ligand-independent and tissue-selective androgen receptor analogue therapy in men with non-metastatic castrate-resistant
inhibition by pyrvinium. ACS Chem Biol 2014;9:692-702. prostate cancer. Eur J Cancer 2015;51:1555-69.
145. Li H, Ban F, Dalal K, Leblanc E, Frewin K, Ma D, Adomat H, Rennie 158. Hamid AR, Verhaegh GW, Smit FP, van Rijt-van de Westerlo C,
PS, Cherkasov A. Discovery of small-molecule inhibitors selectively Armandari I, Brandt A, Sweep FC, Sedelaar JP, Schalken JA.
targeting the DNA-binding domain of the human androgen receptor. J Dutasteride and enzalutamide synergistically suppress prostate tumor
Med Chem 2014;57:6458-67. cell proliferation. J Urol 2015;193:1023-9.
146. Dalal K, Roshan-Moniri M, Sharma A, Li H, Ban F, Hassona MD, 159. Liu C, Lou W, Zhu Y, Yang JC, Nadiminty N, Gaikwad NW,
Hsing M, Singh K, LeBlanc E, Dehm S, Tomlinson Guns ES, Evans CP, Gao AC. Intracrine androgens and AKR1C3 activation
Cherkasov A, Rennie PS. Selectively targeting the DNA-binding confer resistance to enzalutamide in prostate cancer. Cancer Res
domain of the androgen receptor as a prospective therapy for prostate 2015;75:1413-22.
cancer. J Biol Chem 2014;289:26417-29. 160. Liu C, Armstrong CM, Lou W, Lombard A, Evans CP, Gao AC.
147. Loddick SA, Ross SJ, Thomason AG, Robinson DM, Walker GE, Inhibition of AKR1C3 activation overcomes resistance to abiraterone
Dunkley TP, Brave SR, Broadbent N, Stratton NC, Trueman D, in advanced prostate cancer. Mol Cancer Ther 2017;16:35-44.
Mouchet E, Shaheen FS, Jacobs VN, Cumberbatch M, Wilson J, 161. Androgen receptor antagonist ARN-509, abiraterone acetate,
Jones RD, Bradbury RH, Rabow A, Gaughan L, Womack C, Barry prednisone, degarelix, and indomethacin in treating patients with
ST, Robson CN, Critchlow SE, Wedge SR, Brooks AN. AZD3514: localized prostate cancer before surgery. Available from: https://
a small molecule that modulates androgen receptor signaling and www.bioportfolio.com/resources/trial/162934/Androgen-Receptor-
function in vitro and in vivo. Mol Cancer Ther 2013;12:1715-27. Antagonist-ARN-509-Abiraterone-Acetate-Prednisone-Degarelix-
148. Omlin A, Jones RJ, van der Noll R, Satoh T, Niwakawa M, Smith and-Indomethacin-in.html. [Last accessed on 13 Nov 2017]
SA, Graham J, Ong M, Finkelman RD, Schellens JH, Zivi A, Crespo 162. Anighoro A, Bajorath J, Rastelli G. Polypharmacology: challenges
M, Riisnaes R, Nava-Rodrigues D, Malone MD, Dive C, Sloane R, and opportunities in drug discovery. J Med Chem 2014;57:7874-87.
Moore D, Alumkal JJ, Dymond A, Dickinson PA, Ranson M, Clack 163. Boschi D, Giorgis M, Cena C, Talniya NC, Di Stilo A, Morini
G, de Bono J, Elliott T. AZD3514, an oral selective androgen receptor G, Coruzzi G, Guaita E, Fruttero R, Gasco A. Multitarget drugs:
down-regulator in patients with castration-resistant prostate cancer synthesis and preliminary pharmacological characterization of
- results of two parallel first-in-human phase I studies. Invest New zileuton analogues endowed with Dual 5-LO inhibitor and NO-
Drugs 2015;33:679-90. dependent activities. Chem Med Chem 2010;5:1444-9.
149. Yamashita S, Lai KP, Chuang KL, Xu D, Miyamoto H, Tochigi T, 164. Chen M, Adeniji AO, Twenter BM, Winkler JD, Christianson DW,
Pang ST, Li L, Arai Y, Kung HJ, Yeh S, Chang C. ASC-J9 suppresses Penning TM. Crystal structures of AKR1C3 containing an N-(aryl)
castration-resistant prostate cancer growth through degradation of full- amino-benzoate inhibitor and a bifunctional AKR1C3 inhibitor and
length and splice variant androgen receptors. Neoplasia 2012;14:74- androgen receptor antagonist. Therapeutic leads for castrate resistant
83. prostate cancer. Bioorg Med Chem Lett 2012;22:3492-7.
150. Lai KP, Huang CK, Chang YJ, Chung CY, Yamashita S, Li L, Lee SO, 165. Feau C, Arnold LA, Kosinski A, Zhu F, Connelly M, Guy RK. Novel
Yeh S, Chang C. New therapeutic approach to suppress castration- flufenamic acid analogues as inhibitors of androgen receptor mediated
resistant prostate cancer using ASC-J9 via targeting androgen receptor transcription. ACS Chem Biol 2009;4:834-43.
in selective prostate cells. Am J Pathol 2013;182:460-73. 166. Purushottamachar P, Godbole AM, Gediya LK, Martin MS, Vasaitis
151. Liu C, Lou W, Zhu Y, Nadiminty N, Schwartz CT, Evans CP, Gao TS, Kwegyir-Afful AK, Ramalingam S, Ates-Alagoz Z, Njar VC.
AC. Niclosamide inhibits androgen receptor variants expression and Systematic structure modifications of multitarget prostate cancer
overcomes enzalutamide resistance in castration-resistant prostate drug candidate galeterone to produce novel androgen receptor down-
cancer. Clin Cancer Res 2014;20:3198-210. regulating agents as an approach to treatment of advanced prostate
152. Purushottamachar P, Kwegyir-Afful AK, Martin MS, Ramamurthy VP, cancer. J Med Chem 2013;56:4880-98.
Ramalingam S, Njar VC. Identification of novel steroidal androgen 167. Bruno RD, Vasaitis TS, Gediya LK, Purushottamachar P, Godbole
receptor degrading agents inspired by galeterone 3β-imidazole AM, Ates-Alagoz Z, Brodie AMH, Njar VC. Synthesis and biological
carbamate. ACS Med Chem Lett 2016;7:708-13. evaluations of putative metabolically stable analogs of VN/124-1
153. Kwegyir-Afful AK, Ramalingam S, Purushottamachar P, Ramamurthy (TOK-001): head to head anti-tumor efficacy evaluation of VN/124-
VP, Njar VC. Galeterone and VNPT55 induce proteasomal 1 (TOK-001) and abiraterone in LAPC-4 human prostate cancer
degradation of AR/AR-V7, induce significant apoptosis via xenograft model. Steroids 2011;76:1268-79.
cytochrome c release and suppress growth of castration resistant 168. Vasaitis T, Belosay A, Schayowitz A, Khandelwal A, Chopra P,
prostate cancer xenografts in vivo. Oncotarget 2015;6:27440-60. Gediya LK, Guo Z, Fang HB, Njar VC, Brodie AM. Androgen
154. Bradbury RH, Hales NJ, Rabow AA, Walker GE, Acton DG, Andrews receptor inactivation contributes to antitumor efficacy of 17{alpha}-
DM, Ballard P, Brooks NA, Colclough N, Girdwood A, Hancox hydroxylase/17,20-lyase inhibitor 3beta-hydroxy-17-(1H-
UJ, Jones O, Jude D, Loddick SA, Mortlock AA. Small-molecule benzimidazole-1-yl)androsta-5,16-diene in prostate cancer. Mol

360 Journal of Cancer Metastasis and Treatment ¦ Volume 3 ¦ December 12, 2017